Skip to main content
Category

News Archive

Holding place for old articles.

Fierce15

The BioHealth Capital Region’s Adaptive Phage Therapeutics lands on Fierce Biotech’s Fierce 15

By News Archive

Fierce15It’s been a tough year for biotech, so how about a little good news? In between all the layoffs, restructurings and last-ditch strategic option hunting, we wanted to take a moment to shine a spotlight on 15 innovative and truly fierce biotechs.

That didn’t surprise us, because everyone we talk to in the Fierce Biotech universe tells us that science doesn’t stop for the markets. Financing might be a little tough right now, but innovation, breakthroughs and discoveries are all still being made. 

The latest crop of Fierce 15 honorees consists of companies pushing the envelope not only in the lab, in the clinic or on the conference circuit: They are also defining what it means to be a modern biotech company, with modalities ranging from radiopharmaceuticals to cell therapy. Indications as diverse as oncology, neurodegenerative disorders, Pompe disease and even pregnancy complications made the list this year.

Read More
Rich and Judy 250 250 px

Nurturing Tomorrow’s STEM Leaders: A Conversation With Dr. Judy Staveley, Biotechnologist And STEM Advocate

By News Archive

Rich and Judy 250 250 pxExplore the world of scientific mentorship and education with Dr. Judy Staveley, an accomplished Chief Biotechnologist and STEM advocate. In this episode of BioTalk, Dr. Staveley discusses her journey in supporting young scientists and her roles in organizations like the National Association of Academies of Science (NAAS) and the American Junior Academy of Science (AJAS).  

Discover the upcoming NAAS/AJAS STEM EDUCATION CONFERENCE/FUNDRAISER on September 16th and its impact on inspiring the next generation of innovators. Learn about AJAS’s life science support programs that encourage young talents to pursue careers in STEM.  

Dr. Staveley shares insights into STEM education in the BioHealth Capital Region and her personal goals for nurturing young scientists. Join us to uncover the pivotal role of mentorship in shaping the future of STEM.

Listen now via your favorite podcasting platform:

Read More
linshom medical logo

Linshom Medical, Inc. Closes $650K in Series A Round with Investments from Abell Foundation and TEDCO

By News Archive

linshom medical logoBALTIMORE, MARYLAND, UNITED STATES, August 15, 2023/EINPresswire.com/ — Linshom Medical, a Maryland startup medical device company producing innovative advances in respiratory monitoring, received investments of $250K and $400K from Abell Foundation and TEDCO respectively as part of a Series A preferred equity round.

Accurate respiratory monitoring and rapid detection of early respiratory decline are foundational to ensuring positive patient outcomes. Linshom is first to deliver operating room (OR) quality respiratory data to the patient’s bedside. Patients on the general care floor, in the emergency room, in the post anesthesia care unit, and at home do not have the quality of monitoring available in the OR or intensive care unit (ICU). Those technologies are too big, complex and expensive for bedside use. Linshom addresses these barriers by delivering a small, low cost, wearable sensor that delivers highly accurate, continuous, predictive respiratory monitoring (CPRM) to the patient’s bedside.

Read More
b4b 250

BioHealth Innovation Partners with Big4Bio to Amplify the Voice of the BioHealth Capital Region

By News Archive

b4b 250Rockville, MD – BioHealth Innovation (BHI), a founding member of the BioHealth Capital Region (BHCR), announces its strategic partnership with Big4Bio, an national aggregator of news and developments in the life sciences sector. This collaboration aims to share pivotal news and information from the BHCR, which has recently achieved a significant milestone by ranking as a Top 3 BioPharma Cluster in the Genetic Engineering & Biotechnology News “Top 10 US Biopharma Clusters” rankings, to a larger audience beyond the region.

In an era where the life sciences sector is experiencing unparalleled innovation and investment, staying updated with key information is paramount. Big4Bio, focused on its comprehensive coverage of the cornerstone “Big 4” in biosciences and health – drugs, devices, diagnostics, and digital (the “four D’s”), offers daily email newsletters that provide readers with easy-to-scan headlines sourced from hundreds of credible industry sources across eight US Biotech markets. Their commitment to producing individual summaries for the world’s most significant life sciences markets aligns with BHI’s and the BHCR’s vision of fostering growth and innovation in the biotech and life sciences industries.

Read More
Bloomberg Business School

The Johns Hopkins Bloomberg School of Public Health Reaches Next Stage in City Planning Process

By News Archive

Bloomberg Business SchoolThe new 250,000-square-foot facility will support the Bloomberg School’s mission through dynamic workspaces, state-of-the-art classrooms, and a variety of study, collaboration, and event spaces.

The Johns Hopkins Bloomberg School of Public Health shared the latest updates on their planned new building at the Baltimore City Urban Design & Architecture Advisory Panel (UDAAP) meeting this morning.

The new building will be located on existing Johns Hopkins property at the corner of McElderry and Washington streets—adjacent to the division’s main Wolfe Street building and at the heart of the East Baltimore campus. The school has been working with award-winning, London-based architectural firm Hopkins Architects as design architect and Baltimore-based Hord Coplan Macht Inc. as architect of record to design a facility that will meet the demands of public health education, research, and practice well into the future.

Totaling approximately 250,000 gross square feet across seven floors, the new facility will support the school’s mission of inspiring and educating the next generation of public health leaders through dynamic workspaces, state-of-the-art classrooms, and a variety of study, collaboration, and event spaces, including for events and meetings with community groups.

Currently, the school’s academic departments have outgrown their existing spaces, primarily comprised of two separate buildings on North Wolfe Street and North Broadway. The new facility will connect to the Wolfe Street building, bring the core activities of all 10 departments together in one location, and accommodate the Bloomberg School’s growth. The new building will also add much-needed green space to the campus, including an expansion of the existing School of Nursing courtyard that will provide a shared collegial space for rest and relaxation between the two schools.

“We are thrilled to be able to move this building to the next phase of planning, with a thoughtful design for a modern facility that connects to our current Wolfe Street building, in order to foster interdisciplinary collaboration, enhance our teaching and learning experience, and provide new opportunities for community engagement and convening,” said Bloomberg School of Public Health Dean Ellen J. MacKenzie. “Our goal is to create a vibrant space where researchers, practitioners, policymakers, and students collaborate seamlessly to address the most pressing challenges facing us today. We are excited to create an environment that nurtures innovation and incubates ideas that can advance public health globally.”

Click here to read more via JHU’s HUB.

WellDoc250

Welldoc Receives 11th 510(k) Clearance from FDA for Award-Winning Diabetes Platform BlueStar®

By News Archive

WellDoc250COLUMBIA, Md., August 23, 2023 — Welldoc®, a digital health leader revolutionizing chronic care, today announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar® . This clearance immediately follows Welldoc’s 10th 510(k) clearance announcement earlier this month, solidifying the company’s continued leadership in chronic care innovation.

Welldoc’s latest 510(k) enables BlueStar to provide bolus insulin dose recommendations based on the most recent glucose reading and rate of change from a compatible continuous glucose monitoring (CGM) device. This feature enhances BlueStar’s existing digital coaching capabilities, which guide dietary and lifestyle decisions and assist individuals in self-managing their diabetes. Welldoc is the first company to receive clearance for a CGM-informed bolus calculator specifically designed for adults who manage their diabetes with multiple daily injections of insulin.

Read More
Immunomic250

Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme

By News Archive

Immunomic250ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., a privately held, clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced dosing of the first patient in its Phase 1 clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer. The study is being conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts and is being led by Dr. David Reardon, Clinical Director, Center for Neuro-Oncology.

“Dosing of the first patient in the Phase 1 clinical trial of ITI-1001 in patients with GBM is a significant clinical development milestone for Immunomic, representing the first time this pDNA vaccine is being administered in humans,” stated Dr. Teri Heiland, Chief Scientific Officer of Immunomic Therapeutics. “We are eager to evaluate the safety and preliminary efficacy in this patient population, who have only limited treatment options for this devastating disease and expect to read out top-line data in the second quarter of 2025.”

Read More
Horizon250

MM+M: Roche, Horizon lead way for pharma reputation among rare disease patient groups

By News Archive

Horizon250Horizon Therapeutics and Roche rank among the top pharma companies in terms of reputation among rare disease patient groups, according to a recent report compiled by U.K. consultancy PatientView. 

Published Tuesday, the 2022 Corporate Reputation of Pharma survey asked 426 rare disease patient groups representing some 3.3 million patients to assess the performance of 34 drugmakers in the space.

The report noted that pharma has steadily improved its reputation among rare disease patient groups over the past five years. Most respondents praised drugmakers’ abilities to provide products that are beneficial to patients and innovating on breakthrough treatments.

Still, the industry scored lower in 2022 for key activities that are meaningful to these patient populations, including fair pricing policies and access to medicines.

Out of the 34 companies, Horizon was ranked first among rare disease patient groups familiar with the brand, followed by Roche and Takeda Pharmaceuticals. Out of 31 companies, Roche was assessed as the top company by rare disease patient groups working with the company.

Click here to continue reading.

Gillian Henker

CANVASREBEL: Q&A with Gillian Henker, President & Co-Founder, Sisu Global Health.

By News Archive

Gillian HenkerWe’re excited to introduce you to the always interesting and insightful Gillian Henker. We hope you’ll enjoy our conversation with Gillian below.

Hi Gillian, thanks for joining us today. So let’s jump to your mission – what’s the backstory behind how you developed the mission that drives your brand?

At Sisu Global, we set our vision for a world where medical technology enables access to healthcare in every community. In 2010 at Komfo Anokye Teaching Hospital (KATH), I set out to create medical devices to fit the unmet needs of those in resource-limited settings — medical devices that are simple in nature yet impactful in design, serve as a lifesaving intervention for patients, and directly influence the entire healthcare ecosystem.

Read More
HHS logo

Project NextGen Awards Over $1.4 Billion to Develop the Future of COVID-19 Vaccines and Therapeutics

By News Archive

HHS logoFunding includes $1 billion for vaccine clinical trials, $326 million for a new monoclonal antibody, and $100 million to explore novel vaccine and therapeutic technologies

Today, the U.S. Department of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response (ASPR), awarded more than $1.4 billion for Project NextGen to support the development of a new generation of tools and technologies to protect against COVID-19 for years to come.

The awards announced today follow extensive coordination with industry partners and include support for clinical trials that will enable the rapid development of even more effective and longer-lasting coronavirus vaccines, a new monoclonal antibody, and transformative technologies to streamline manufacturing processes.

“Project NextGen is a key part of the Biden-Harris Administration’s commitment to keeping people safe from COVID-19 variants,” said HHS Secretary Xavier Becerra. “These awards are a catalyst for the program – kickstarting efforts to more quickly develop vaccines and continue to ensure availability of effective treatments.”

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.